The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea
Open accessAbstract
BACKGROUND & AIMS Which antiviral agent between entecavir (ETV) vs. tenofovir disoproxil fumarate (TDF) is superior in improving prognosis for chronic hepatitis B (CHB) is unclear. Here, we assessed the ability of these two antivirals to prevent liver-disease progression in treatment-naïve CHB patients. METHODS From 2012 to 2014, treatment-naïve CHB patients who received ETV or TDF as a first-line antiviral agent were recruited from four academic teaching hospitals. Patients with decompensated cirrhosis or hepatocellular carcinoma (HCC) at enrollment were excluded. Cumulative probabilities of HCC and death or orthotopic liver transplant (OLT) were assessed. RESULTS In total, 2,897 patients (1,484 and 1,413 in the ETV and TDF groups, respectively) were recruited. The annual HCC incidence was statistically not different between the ETV and TDF groups (1.92 vs. 1.69 per 100 person-years [PY], respectively; adjusted hazard ratio [HR], 0.975 [p=0.852] by multivariate analysis). Propensity score (PS)-matched and inverse probability of treatment weighting (ITPW) analyses yielded similar patterns of results (HR, 1.021 [p=0.884] and 0.998 [p=0.988], respectively). The annual incidence of death or OLT was statistically not different between the ETV and TDF groups (0.52 vs. 0.53 per 100PY, respectively; adjusted HR, 1.202 [p=0.451]). PS-matched and ITPW analyses yielded similar patterns of results (HR, 1.248 [p=0.385] and 1.239 [p=0.360], respectively). These findings were consistently reproduced in patients with compensated cirrhosis (all p>0.05). CONCLUSIONS The overall prognosis in terms of HCC and death or OLT were statistically not different between the ETV and TDF groups. Further studies are needed to validate our results. LAY SUMMARY: - Which antiviral agent between entecavir (ETV) vs. tenofovir disoproxil fumarate (TDF) is superior in improving prognosis for chronic hepatitis B (CHB) is unclear. - The overall prognosis in terms of HCC and death or OLT was statistically not different between the ETV and TDF groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Cited by
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Metadata
- Authors
- Kim, S. U., Seo, Y. S., Lee, H. A., Kim, M. N., Lee, Y. R., Lee, H. W., Park, J. Y., Kim, D. Y., Ahn, S. H., Han, K.-H., Hwang, S. G., Rim, K. S., Um, S. H., Tak, W. Y., Kweon, Y. O., Kim, B. K., & Park, S. Y.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 71
- Issue
- 3
- Pages
- 456-464
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2931761340
- Cited by
- 166
- References
- 3
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.